EDITORIAL Predictor of Amyloidosis Outcomes? See Article by Hanson et al Jose Nativi-Nicolau, MD The future depends on what you do today. ―Mahatma Gandhi biomarker is defined by the National Institutes of Health Biomarkers Def- initions Working Group as “a characteristic that is objectively measured A and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.” Several biomarkers have been studied in recent years; however, few are used in clinical practice. According to the US Preventive Services Task Force, the potential impact of a novel risk factor is based on the following: (1) its predictive ability, (2) its preva- lence in the target population, (3) the number of intermediate-risk individuals who are reclassified as high risk when the risk factor is applied, and (4) the net benefit (benefits minus harms) that would accrue to these high-risk individuals if they were managed according to guidelines for high-risk patients. Amyloidosis involves the transformation of a precursor protein into an insol- uble extracellular fibril that interferes with the function of the organs affected (Figure). The most common precursors include immunoglobulin light chains (AL amyloidosis), wild-type transthyretins (ATTRwt), and genetically mutated trans- thyretins (ATTRm). The field
Circulation: Heart Failure – Wolters Kluwer Health
Published: Feb 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud